JP2016504362A - アルブミンおよびパクリタキセルのナノ粒子組成物 - Google Patents

アルブミンおよびパクリタキセルのナノ粒子組成物 Download PDF

Info

Publication number
JP2016504362A
JP2016504362A JP2015550675A JP2015550675A JP2016504362A JP 2016504362 A JP2016504362 A JP 2016504362A JP 2015550675 A JP2015550675 A JP 2015550675A JP 2015550675 A JP2015550675 A JP 2015550675A JP 2016504362 A JP2016504362 A JP 2016504362A
Authority
JP
Japan
Prior art keywords
composition
albumin
paclitaxel
less
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015550675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016504362A5 (enExample
Inventor
ニール ピー． デサイ，
ニール ピー． デサイ，
Original Assignee
アブラクシス バイオサイエンス， エルエルシー
アブラクシス バイオサイエンス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブラクシス バイオサイエンス， エルエルシー, アブラクシス バイオサイエンス， エルエルシー filed Critical アブラクシス バイオサイエンス， エルエルシー
Publication of JP2016504362A publication Critical patent/JP2016504362A/ja
Publication of JP2016504362A5 publication Critical patent/JP2016504362A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2015550675A 2012-12-28 2013-12-19 アルブミンおよびパクリタキセルのナノ粒子組成物 Pending JP2016504362A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261747123P 2012-12-28 2012-12-28
US61/747,123 2012-12-28
US13/794,705 2013-03-11
US13/794,705 US20140186447A1 (en) 2012-12-28 2013-03-11 Nanoparticle compositions of albumin and paclitaxel
PCT/US2013/076630 WO2014105644A1 (en) 2012-12-28 2013-12-19 Nanoparticle compositions of albumin and paclitaxel

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018030637A Division JP2018087241A (ja) 2012-12-28 2018-02-23 アルブミンおよびパクリタキセルのナノ粒子組成物

Publications (2)

Publication Number Publication Date
JP2016504362A true JP2016504362A (ja) 2016-02-12
JP2016504362A5 JP2016504362A5 (enExample) 2017-02-02

Family

ID=51017455

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015550675A Pending JP2016504362A (ja) 2012-12-28 2013-12-19 アルブミンおよびパクリタキセルのナノ粒子組成物
JP2018030637A Pending JP2018087241A (ja) 2012-12-28 2018-02-23 アルブミンおよびパクリタキセルのナノ粒子組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018030637A Pending JP2018087241A (ja) 2012-12-28 2018-02-23 アルブミンおよびパクリタキセルのナノ粒子組成物

Country Status (19)

Country Link
US (2) US20140186447A1 (enExample)
EP (1) EP2938340A4 (enExample)
JP (2) JP2016504362A (enExample)
KR (1) KR20150100903A (enExample)
CN (1) CN105007912A (enExample)
AU (1) AU2013370955B2 (enExample)
BR (1) BR112015015319A2 (enExample)
CA (1) CA2896288A1 (enExample)
CR (1) CR20150386A (enExample)
HK (1) HK1216611A1 (enExample)
IL (1) IL239593A0 (enExample)
MX (1) MX2015008361A (enExample)
NI (1) NI201500090A (enExample)
NZ (1) NZ630912A (enExample)
PH (1) PH12015501486B1 (enExample)
RU (1) RU2663687C2 (enExample)
SG (1) SG11201505111TA (enExample)
WO (1) WO2014105644A1 (enExample)
ZA (1) ZA201504762B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536052A (ja) * 2017-10-03 2020-12-10 クリティテック・インコーポレイテッド 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達
JP2022553426A (ja) * 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
JP2024540366A (ja) * 2021-11-03 2024-10-31 エスエヌ バイオサイエンス インコーポレイテッド 粒度分布維持安定性が改善されたアルブミン結合タキサンナノ粒子の製造方法

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
TWI417114B (zh) 2005-08-31 2013-12-01 Abraxis Bioscience Llc 具有增強穩定性之弱水溶性藥物之組合物及其製備方法
CA2672618C (en) 2006-12-14 2021-03-02 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
DK2155188T3 (da) * 2007-06-01 2013-11-04 Abraxis Bioscience Llc Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
CN102460167B (zh) 2009-04-15 2015-07-22 阿布拉科斯生物科学有限公司 不含朊病毒的纳米颗粒组合物和方法
ES2580135T3 (es) 2010-03-26 2016-08-19 Abraxis Bioscience, Llc Métodos de tratamiento de carcinoma hepatocelular
AU2011232862B2 (en) 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
NZ628423A (en) 2010-03-29 2016-03-31 Abraxis Bioscience Llc Methods of treating cancer
RU2576609C2 (ru) 2010-06-04 2016-03-10 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечение рака поджелудочной железы
CA3063641A1 (en) 2011-04-28 2012-11-01 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
PT2707030T (pt) 2011-05-09 2020-05-22 Mayo Found Medical Education & Res Tratamentos de cancro
DK2790675T3 (da) 2011-12-14 2019-09-09 Abraxis Bioscience Llc Anvendelse af polymerexcipienser til frysetørring eller frysning af partikler
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
NZ630392A (en) 2013-03-12 2016-10-28 Abraxis Bioscience Llc Methods of treating lung cancer
RU2015143490A (ru) 2013-03-14 2017-04-26 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
WO2014191569A1 (en) 2013-05-30 2014-12-04 Nanobiotix Pharmaceutical composition, preparation and uses thereof
JP6695286B2 (ja) 2014-06-13 2020-05-20 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ リンパ腫の処置
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
CN104224750A (zh) * 2014-09-17 2014-12-24 四川大学 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201628644A (zh) * 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備及其用途
US10765632B2 (en) 2014-11-25 2020-09-08 Curadigm Sas Methods of improving delivery of compounds for therapy, prophylaxis or diagnosis
PT3229776T (pt) 2014-11-25 2023-08-17 Curadigm Sas Composição farmacêutica combinando pelo menos duas nanopartícuas distintas e um composto farmacêutico, preparaçâo e suas utilizações
AR102780A1 (es) 2014-11-25 2017-03-22 Nanobiotix Composiciones farmacéuticas, su preparación y sus usos
US10527604B1 (en) * 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
MA43100A (fr) 2015-05-28 2018-09-05 Nanobiotix Nanoparticules à utiliser en tant que vaccin thérapeutique
HUE070408T2 (hu) 2015-06-29 2025-06-28 Abraxis Bioscience Llc Szirolimuszt és albumint tartalmazó nanorészecskék epitelioid sejtes tumorok kezelésében történõ alkalmazásra
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
CA3014531A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165439A1 (en) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
EP3432926A4 (en) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research METHOD FOR REDUCING THE TOXICITY OF CHEMOTHERAPEUTICS
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
AU2017321798B2 (en) 2016-09-01 2023-06-15 Mayo Foundation For Medical Education And Research Methods and compositions for targeting T-cell cancers
MX2019002474A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
RU2756892C2 (ru) 2016-09-06 2021-10-06 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
EP3509635A1 (en) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
WO2018048816A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
CN106420665B (zh) * 2016-10-28 2019-04-16 浙江省林业科学研究院 一种包裹紫杉烷类药物的白蛋白纳米颗粒载体的制备方法
WO2019183146A1 (en) 2018-03-20 2019-09-26 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
US20220401374A1 (en) * 2019-09-13 2022-12-22 Purdue Research Foundation Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules
KR20220113699A (ko) * 2019-11-11 2022-08-16 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물에 대한 바이오마커
WO2021158937A1 (en) * 2020-02-05 2021-08-12 The Johns Hopkins University Bortezomib-loaded nanoparticles
WO2024118542A1 (en) * 2022-11-28 2024-06-06 Takeda Vaccines, Inc. A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂
WO2011119988A1 (en) * 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Methods of treatment of hepatocellular carcinoma
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
EP1100494A1 (en) * 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Pharmaceutically composition comprising an aqueous solution of paclitaxel and albumin
JP4798832B2 (ja) * 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 ヒト血清アルブミン多量体の除去方法
NZ598588A (en) * 2009-08-25 2014-05-30 Abraxis Bioscience Llc Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119988A1 (en) * 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Methods of treatment of hepatocellular carcinoma
WO2012092712A1 (zh) * 2011-01-07 2012-07-12 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的纳米颗粒冷冻干燥粉末制剂
CN102078306A (zh) * 2011-01-11 2011-06-01 无锡圆容生物医药股份有限公司 一种含有重组人血白蛋白的紫杉醇纳米颗粒冷冻干燥制剂

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536052A (ja) * 2017-10-03 2020-12-10 クリティテック・インコーポレイテッド 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達
JP7792750B2 (ja) 2017-10-03 2025-12-26 クリティテック・インコーポレイテッド 癌の治療のための免疫療法剤の全身送達と組み合わせた抗腫瘍粒子の局所送達
JP2022553426A (ja) * 2019-10-28 2022-12-22 アブラクシス バイオサイエンス， エルエルシー アルブミンおよびラパマイシンの医薬組成物
JP2024540366A (ja) * 2021-11-03 2024-10-31 エスエヌ バイオサイエンス インコーポレイテッド 粒度分布維持安定性が改善されたアルブミン結合タキサンナノ粒子の製造方法
JP7786770B2 (ja) 2021-11-03 2025-12-16 エスエヌ バイオサイエンス インコーポレイテッド 粒度分布維持安定性が改善されたアルブミン結合タキサンナノ粒子の製造方法

Also Published As

Publication number Publication date
JP2018087241A (ja) 2018-06-07
AU2013370955B2 (en) 2018-12-06
KR20150100903A (ko) 2015-09-02
RU2015131141A (ru) 2017-02-03
SG11201505111TA (en) 2015-07-30
RU2663687C2 (ru) 2018-08-08
CR20150386A (es) 2015-10-07
IL239593A0 (en) 2015-08-31
US20140186447A1 (en) 2014-07-03
HK1216611A1 (zh) 2016-11-25
PH12015501486B1 (en) 2020-12-16
NZ630912A (en) 2017-05-26
EP2938340A1 (en) 2015-11-04
CA2896288A1 (en) 2014-07-03
ZA201504762B (en) 2016-10-26
US20190192477A1 (en) 2019-06-27
MX2015008361A (es) 2016-03-11
NI201500090A (es) 2015-12-22
PH12015501486A1 (en) 2015-09-21
EP2938340A4 (en) 2016-08-03
CN105007912A (zh) 2015-10-28
BR112015015319A2 (pt) 2017-07-11
WO2014105644A1 (en) 2014-07-03
AU2013370955A1 (en) 2015-07-16

Similar Documents

Publication Publication Date Title
JP2018087241A (ja) アルブミンおよびパクリタキセルのナノ粒子組成物
JP6685875B2 (ja) 治療薬の組み合わせおよび投与の様式ならびに併用療法
JP6257324B2 (ja) 膵臓がんの処置方法
JP6216721B2 (ja) 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用
KR101943230B1 (ko) 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
US20170007569A1 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
NO20190526A1 (no) Sammensetninger og fremgangsmåter for fremstilling av lite vannoppløselige medikamenter med økt stabilitet
KR20170101925A (ko) 병용 요법
WO2023208009A1 (zh) 一种速溶型纳米粒子组合物及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190205